Top of the morning to you. A shiny day is unfolding here on the Pharmalot corporate campus, where we are hustling assorted short people off to their last moments at the local school houses. This is cause for celebration. So please join us for a cup or two of stimulation. And we hope you will check out our2 pm EDT webinar today on Social Media. Meanwhile, here are some tidbits from around the big, old world. Have a great day...
European Union Approves Lilly Bydureon Diabetes Drug (Associated Press)
Dentsply In Talks To Buy AstraZeneca Unit (Reuters)
EMA Proposes Waiving Inspections Of US Plants Sometimes (InPharma Technologist)
Calpers Taps CVS/Caremark To Manage Benefits (San Francisco Business Times)
Abbott Hit By $4M Diagnostic Theft In Kentucky (Securing Pharma)
Roche And Curis Skin Cancer Drug Closer To FDA Filing (Pharma Times)
Concert Gets $4M From Glaxo For HIV Candidate (Boston Business Journal)
Pfizer And Acura Win FDA OK For Abuse-Free Painkiller (Bloomberg News)
Medicis Drugs Bests Botox In Tackling Crow's Feet In Study (Reuters)
Icahn Criticizes Forest For Defending Embattled CEO (Reuters)
Scientists Develop New Approach For Cancer Vaccine (Reuters)
Patient Groups Urge Wider Listings For Drug Subsidies (Sydney Morning Herald)
EDITOR’S NOTE: Please check this post for updates throughout the morning
2 Comments
They say there is an epidemic of diabetes in the US, ergo the hot market for boosted glucose test strips from Abbott.
“We're looking to move from confidence in, to reliance on”, said David Cockburn, head of manufacturing and quality compliance at the EMA...Waiving the need to inspect US plants that meet certain, as yet undefined, criteria would be a clear move in this direction but an agreement still needs to be reached.
The FDA has a big problem on their hands because pushing U.S. plant inspection might drive pharma to close plants in US and reopen in foreign countries where there is less FDA presence.
Looks like instead of increasing the number and quality of inspections in some foreign countries, EMA and potentially the FDA are looking to resolve the problem by lowering the overall quality and safety of prescription drug/drug component manufacturers.
I can't help but think that long term, this might be bad and lead to increased costs for stockholders, pateints and others.